Immunogenicity of Biosimilars

Immunogenicity is the propensity of therapeutic biologics to elicit immune responses to themselves and to related proteins or to trigger undesirable clinical outcomes or immunologically related non-clinical effects. When we think about immunogenicity, we mostly consider very minor tweaks to the manufacturing process, adjustments to the purifying procedure, and potential post-translational alterations. Strategies for evaluating the immunogenicity of biosimilars are developed on a case-by-case basis. The evaluation's goal is to identify potential variations in the frequency and intensity of human immunological responses between the biosimilar candidate and the reference product. Small (indiscernible) changes between biosimilars and the original medications could cause patients to develop unexpected immune responses, which is a big worry

    Related Conference of Immunogenicity of Biosimilars

    October 24-25, 2024

    8th International Conference on Protein Engineering

    Zurich, Switzerland

    Immunogenicity of Biosimilars Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in